APA (7th ed.) Citation

Woźniak, E., Woźniak, A., Pawlos, A., Broncel, M., Satała, J., Bukowska, B., & Gorzelak-Pabiś, P. (2025). Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. International Journal of Molecular Sciences, 26(21), 10529. https://doi.org/10.3390/ijms262110529

Chicago Style (17th ed.) Citation

Woźniak, Ewelina, Agnieszka Woźniak, Agnieszka Pawlos, Marlena Broncel, Joanna Satała, Bożena Bukowska, and Paulina Gorzelak-Pabiś. "Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia." International Journal of Molecular Sciences 26, no. 21 (2025): 10529. https://doi.org/10.3390/ijms262110529.

MLA (9th ed.) Citation

Woźniak, Ewelina, et al. "Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia." International Journal of Molecular Sciences, vol. 26, no. 21, 2025, p. 10529, https://doi.org/10.3390/ijms262110529.